USFDA approval to Zydus to market Teriflunomide tablets for MS relapse
Zydus group now has 237 approvals from the USFDA and has so far filed over 340 abbreviated new drug applications.
New Delhi: Drug firm Zydus Cadila recently said that it has received an approval from the US health regulator to market Teriflunomide tablets, used to treat relapsing forms of multiple sclerosis (MS). The company has received an approval from the United States Food and Drug Administration (USFDA) to market Teriflunomide Tablets - 7 mg and 14 mg - in the US market, Zydus Cadila said in a statement.
"It will be manufactured at the group's formulations manufacturing facility at special economic zone (SEZ), Ahmedabad," it added.
Farhat Nasim joined Medical Dialogue an Editor for the Business Section in 2017. She Covers all the updates in the Pharmaceutical field, Policy, Insurance, Business Healthcare, Medical News, Health News, Pharma News, Healthcare and Investment. She is a graduate of St.Xavier’s College Ranchi. She can be contacted at editorial@medicaldialogues.in Contact no. 011-43720751 To know about our editorial team click here
Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2020 Minerva Medical Treatment Pvt Ltd